Shots:

• The approval is based on P-III CheckMate -9LA study assessing Opdivo + Yervoy combined with two cycles of platinum-doublet CT vs CT (four cycles followed by optional pemetrexed maintenance therapy if eligible) as a 1L treatment in patients with metastatic/ recurrent NSCLC regardless of PD-L1 expression and histology
• The study met its 1EPs & 2EPS- demonstrating OS- PFS- and ORR for the dual immunotherapy. @12.7mos. follow up mOS (15.6 mos. vs 10.9 mos.)
• The approval marks the availability of the first dual immuno-oncology in NSCLC treatment in Canada

­ Ref: BMS | Image: BMS